Aarhus University Seal / Aarhus Universitets segl

Anders Kjærsgaard

Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality: A Danish population-based study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


  • Anne Mette Falstie-Jensen
  • ,
  • Anders Kjærsgaard
  • Ebbe Laugaard Lorenzen, Odense Universitetshospital, Syddansk Universitet
  • ,
  • Jeanette Dupont Jensen, Odense Universitetshospital, Syddansk Universitet
  • ,
  • Kristin Valborg Reinertsen, Oslo University Hospital-Rikshospitalet
  • ,
  • Olaf M. Dekkers
  • Marianne Ewertz, Odense Universitetshospital, Syddansk Universitet
  • ,
  • Deirdre P. Cronin-Fenton

Background: Hypothyroidism may occur as a late effect of breast cancer-directed treatment, particularly after radiotherapy, but little is known whether hypothyroidism affects the prognosis after breast cancer. We investigated the association between hypothyroidism and breast cancer recurrence, and all-cause mortality. Methods: In this population-based cohort study, we used national medical registries to identify all Danish women 35 years or older diagnosed with stage I-III, operable breast cancer between 1996 and 2009. Hypothyroidism was defined as hospital diagnoses ascertained via diagnostic codes, or as prescriptions for levothyroxine. Two analytic models were used: (i) hypothyroidism present at the time of the breast cancer diagnosis (prevalent) and (ii) hypothyroidism diagnosed during follow-up as a time-varying exposure lagged by 1 year (incident). Breast cancer recurrence was defined as any local, regional, or distant recurrence or contralateral breast cancer. All-cause mortality included death from any cause in any setting. We used Cox regression models accounting for competing risks to compute adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of breast cancer recurrence and all-cause mortality. Results: The study cohort included 35,463 women with breast cancer with 212,641 person-years of follow-up. At diagnosis, 1272 women had hypothyroidism and 859 women developed hypothyroidism during follow-up. In total, 5810 patients developed recurrent breast cancer. Neither prevalent nor incident hypothyroidism was associated with breast cancer recurrence (adjusted HR prevalent 1.01, 95% CI 0.87-1.19; adjusted HR incident 0.93, 95% CI 0.75-1.16, respectively). Furthermore, no differences were seen for all-cause mortality for prevalent or incident hypothyroidism (adjusted HR prevalent 1.02, 95% CI 0.92-1.14, and HR incident 1.08, 95% CI 0.95-1.23, respectively). Stratification by menopausal status, oestrogen receptor status, chemotherapy, or radiotherapy did not alter the estimates. Conclusions: Hypothyroidism present at diagnosis or during follow-up was not associated with breast cancer recurrence or all-cause mortality in women with breast cancer. Our findings provide reassurance to patients and their physicians that hypothyroidism is unlikely to impact on the clinical course of breast cancer or survival.

TidsskriftBreast Cancer Research
StatusUdgivet - 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 149729648